Methylprednisolone versus dexamethasone in patients with COVID-19
Phase 3
Completed
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN44151777
- Lead Sponsor
- Hospital do Rocio
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
1. Age =18 years.
2. Confirmed or suspected infection for COVID-19.
3. Need for hospitalization, infirmary or intensive care unit (ICU).
4. Chest tomography with image compatible with COVID-19.
Exclusion Criteria
1. Known history of allergy to metrilprednisolone.
2. Use of corticosteroids for another condition.
3. Patient's refusal to participate in the study.
4. Pregnant or breastfeeding women.
5. Contraindication to the use of corticosteroids.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All-cause mortality rates at 28 days after randomization measured using patient records
- Secondary Outcome Measures
Name Time Method <br> Measured using patient records:<br> 1. Length of hospital stay<br> 2. Need or not for referral to the ICU<br> 3. Length of ICU stay between randomization and day 28<br> 4. Time of mechanical ventilation between randomization and day 28<br> 5. Changes in laboratory standards after 72 hours, 7 days and 10 days of randomization<br>